Colorado-based Replidyne (RDYN) may fit in well with the ABT antibiotic portfolio, and a chance to grab the platform company on the cheap. More here http://CLSDF.com
I don't know what "ABT antibiotics portfolio" you're referring to.Biaxin which is allowed to expire its own timely death, is the last one.Among the areas of pharmaceutical drug development there is NO antibiotics area of concentration.
Yes, I agree.Phy
I think you may be right.Phy